Weekly Top News – Psoriasis – July 1, 2019

July 2, 2019

Cosentyx (secukinumab) / Novartis
Cosentyx clinical trial estimate: Data from P3 EXCEED trial (NCT02745080) for psoriatic arthritis in 2020 (J.P. Morgan) – Jun 28, 2019 – A subscription to Thomson ONE is required to gain full access to report 67502119; Page no: 1; REPORT TITLE: “European Pharma & Biotech : EULAR 2019 wrap up: Key takeaways for Novartis, Roche, GSK, Galapagos, UCB and MorphoSys”; AUTHOR: Quigley, James, et al; DATE: 06/17/2019


Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
A Clinical Trial of Tildrakizumab in Pediatric Subjects With Moderate to Severe Chronic Plaque Psoriasis(clinicaltrials.gov) – Jun 25, 2019 – P2/3; N=120; Not yet recruiting; Sponsor: Sun Pharma Global FZE


Tremfya (guselkumab) / J&J
G-PLUS: A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis(clinicaltrials.gov) – Jun 26, 2019 – P3b; N=105; Not yet recruiting; Sponsor: Janssen-Cilag Ltd.


Cosentyx (secukinumab) / Novartis
FUTURE5: Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis (clinicaltrials.gov) – Jun 28, 2019 – P3; N=997; Completed; Sponsor: Novartis Pharmaceuticals; Active, not recruiting –> Completed


Otezla (apremilast) / Celgene
Bristol-Myers Squibb plans to sell Celgene’s Otezla in attempt to expedite acquisition (BioSpace) – Jun 24, 2019 – “As the U.S. Federal Trade Commission (FTC) reviews Bristol-Myers Squibb’s acquisition of Celgene, Bristol-Myers indicates it plans to divest Celgene’s psoriasis and psoriatic arthritic drug Otezla (apremilast)….The divestiture is apparently in response to FTC concerns over the merger. The companies expect the deal to close at the end of this year or in early 2020.”


Duobrii (halobetasol/tazarotene) / Bausch Health
Bausch Health announces U.S. launch of Duobrii (halobetasol propionate and tazarotene) lotion 0.01%/0.045% for plaque psoriasis in adults (PRNewswire) – Jun 25, 2019 – “Bausch Health Companies…and its dermatology business, Ortho Dermatologics…today announced that DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, will be available commercially to health care professionals starting this week….DUOBRII Lotion is priced at $825 for a supply of a 100-gram tube…through the company’s access program, most eligible, commercially insured patients will have a co-pay as little as $25.”

No Comments

Post a Comment